Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy
Introduction. Helicobacter pylori eradication therapy has the potential burden of antibiotic-associated gastrointestinal (GI) side effects. The occurrence of side effects is among the major drawbacks of such regimens. GI manifestations may be related to alterations in the intestinal microflora. Prob...
Saved in:
Main Authors: | Veronica Ojetti, Giovanni Bruno, Maria Elena Ainora, Giovanni Gigante, Gianluca Rizzo, Davide Roccarina, Antonio Gasbarrini |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Gastroenterology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2012/740381 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of Lactobacillus reuteri DSMZ17648 for Helicobacter pylori eradication therapy (Review of literature and advisory council resolution, February 28, 2018)
by: V. T. Ivashkin, et al.
Published: (2018-08-01) -
Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan
by: Wei-Chen Tai, et al.
Published: (2013-01-01) -
Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections
by: Hyo Jun Ahn, et al.
Published: (2017-01-01) -
Effects of Dietary Supplementation with <i>Lactobacillus reuteri</i> Postbiotics on Growth Performance, Intestinal Flora Structure and Plasma Metabolome of Weaned Piglets
by: Dongfeng Sun, et al.
Published: (2025-01-01) -
Lactobacillus reuteri ZJ617 attenuates metabolic syndrome via microbiota-derived spermidine
by: Yanfei Ma, et al.
Published: (2025-01-01)